p-EGFR Antibody (6D373): sc-71778

p-EGFR Antibody (6D373) is a mouse monoclonal IgG1 antibody that detects synthetic phosphopeptide corresponding to amino acid residues surrounding Serine 1047 of EGFR of human origin in mouse, rat, human, and canine samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-p-EGFR antibody (6D373) recognizes phosphorylated forms of EGFR, which is crucial for mediating cellular responses to growth factors. EGFR is primarily located on the cell surface, where binding with ligands like epidermal growth factor (EGF) or transforming growth factor alpha (TGFα) triggers dimerization and autophosphorylation. This activation initiates a cascade of downstream signaling pathways that regulate cell proliferation, differentiation, and survival, making EGFR a vital component in various physiological processes and a key player in oncogenesis when dysregulated. Phosphorylation of specific tyrosine residues, such as Tyr 1092 and Tyr 1173, enables recruitment of signaling proteins like GRB2, which further propagate the signaling cascade. Understanding EGFR activation dynamics and interactions remains critical for developing targeted cancer therapies, as aberrant EGFR signaling appears in numerous malignancies. p-EGFR monoclonal antibody (6D373) serves as an indispensable tool for studying EGFR phosphorylation and signaling, advancing our understanding of EGFR function in both normal physiology and cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-EGFR Antibody (6D373) References:

1. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.  |  Hiraishi, Y., et al. 2006. Pathol Oncol Res. 12: 87-91. PMID: 16799709
2. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.  |  McMillen, E., et al. 2010. Exp Lung Res. 36: 531-7. PMID: 20939760
3. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact.  |  Li, CF., et al. 2012. Ann Surg Oncol. 19: 443-54. PMID: 21761100
4. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.  |  Wang, F., et al. 2012. J Exp Clin Cancer Res. 31: 65. PMID: 22901364
5. Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer.  |  An, SJ., et al. 2012. Exp Ther Med. 4: 226-230. PMID: 23139712
6. EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer.  |  Romanitan, M., et al. 2013. Anticancer Res. 33: 1575-83. PMID: 23564800
7. Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis.  |  Shan, ZZ., et al. 2017. Oncol Lett. 14: 2859-2863. PMID: 28927043
8. miR-22-3p enhances the intrinsic regenerative abilities of primary sensory neurons via the CBL/p-EGFR/p-STAT3/GAP43/p-GAP43 axis.  |  Li, B., et al. 2020. J Cell Physiol. 235: 4605-4617. PMID: 31663116
9. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.  |  Hong, X., et al. 2022. Medicine (Baltimore). 101: e28507. PMID: 35060503
10. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma.  |  Zhou, Z., et al. 2024. Cell Commun Signal. 22: 303. PMID: 38831321

The preferred EGFR antibody is EGFR Antibody (528): sc-120.